Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine

References

• Bech P Cialdella P Haugh MC Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression Br J Psychiatry 2000 176 421 428 10912216
   PubMed Web of Science ®Google Scholar
• Papakostas GI Charles D Fava M Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder World J Biol Psychiatry 2010 11 2 Pt 2 300 307 20218793
   PubMed Web of Science ®Google Scholar
• Cipriani A Furukawa TA Geddes JR MANGA Study Group Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis J Clin Psychiatry 2008 69 11 1732 1742 19026250
   PubMed Web of Science ®Google Scholar
• Furukawa TA McGuire H Barbui C Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review BMJ 2002 325 7371 991 12411354
   PubMed Web of Science ®Google Scholar
• Furukawa T McGuire H Barbui C Low dosage tricyclic antidepressants for depression [review] Cochrane Database Syst Rev 2003 3 CD003197 12917952
   PubMedGoogle Scholar
• Steffens DC Krishnan KR Helms MJ Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis Depress Anxiety 1997 6 1 10 18 9394870
   PubMedGoogle Scholar
• Papakostas GI Homberger CH Fava M A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder J Psychopharmacol (Oxford) 2008 22 8 843 848 18308801
   PubMed Web of Science ®Google Scholar
• Machado M Iskedjian M Ruiz I Einarson TR Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials Curr Med Res Opin 2006 22 9 1825 1837 16968586
   PubMed Web of Science ®Google Scholar
• Thase ME Pritchett YL Ossanna MJ Swindle RW Xu J Detke MJ Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder J Clin Psychopharmacol 2007 27 6 672 676 18004135
   PubMed Web of Science ®Google Scholar
• Anderson IM Meta-analytical studies on new antidepressants Br Med Bull 2001 57 161 178 11719915
   PubMed Web of Science ®Google Scholar
• Serretti A Chiesa A Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis J Clin Psychopharmacol 2009 29 3 259 266 19440080
   PubMed Web of Science ®Google Scholar
• Williams VS Edin HM Hogue SL Fehnel SE Baldwin DS Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey J Psychopharmacol (Oxford) 2010 24 4 489 496 19329551
   PubMed Web of Science ®Google Scholar
• Strohmaier J Wüst S Uher R Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR World J Biol Psychiatry 2011 12 7 528 538 21388237
   PubMed Web of Science ®Google Scholar
• Safarinejad MR Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study J Psychopharmacol (Oxford) 2011 25 3 370 378 20080928
   PubMed Web of Science ®Google Scholar
• Safarinejad MR The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study BJU Int 2010 106 6 840 847 20067456
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ Filion KB Yavin D Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials CMAJ 2005 179 2 135 144 18625984
   PubMed Web of Science ®Google Scholar
• Maneeton N Maneeton B Srisurapanont M Martin SD Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials Psychiatry Clin Neurosci 2011 65 7 611 617 22176279
   PubMed Web of Science ®Google Scholar
• Stahl SM Pradko JF Haight BR Modell JG Rockett CB Learned-Coughlin S A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor Prim Care Companion J Clin Psychiatry 2004 6 4 159 166 15361919
   PubMedGoogle Scholar
• Hoehn-Saric R Lipsey JR McLeod DR Apathy and indifference in patients on fluvoxamine and fluoxetine J Clin Psychopharmacol 1990 10 5 343 345 2124218
   PubMed Web of Science ®Google Scholar
• Opbroek A Delgado PL Laukes C Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002 5 2 147 151 12135539
   PubMed Web of Science ®Google Scholar
• Lee SI Keltner NL Antidepressant apathy syndrome Perspect Psychiatr Care 2005 41 4 188 192 16297025
   PubMed Web of Science ®Google Scholar
• Demyttenaere K Jaspers L Review: Bupropion and SSRI-induced side effects J Psychopharmacol (Oxford) 2008 22 7 792 804 18308785
   PubMed Web of Science ®Google Scholar
• Bolling MY Kohlenberg RJ Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction Psychother Psychosom 2004 73 6 380 385 15479994
   PubMed Web of Science ®Google Scholar
• Schmitt AB Bauer M Volz HP Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity Eur Arch Psychiatry Clin Neurosci 2009 259 6 329 339 19255709
   PubMed Web of Science ®Google Scholar
• Schueler YB Koesters M Wieseler B A systematic review of duloxetine and venlafaxine in major depression, including unpublished data Acta Psychiatr Scand 2011 123 4 247 265 20831742
   PubMed Web of Science ®Google Scholar
• Eckert L Lançon C Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons BMC Psychiatry 2006 6 30 16867188
   PubMed Web of Science ®Google Scholar
• de Silva VA Hanwella R Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies Int Clin Psychopharmacol 2012 27 1 8 16 21971532
   PubMed Web of Science ®Google Scholar
• Uher R Farmer A Maier W Measuring depression: comparison and integration of three scales in the GENDEP study Psychol Med 2008 38 2 289 300 17922940
   PubMed Web of Science ®Google Scholar
• Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated Mar 2011) The Cochrane Collaboration 2011 Available from: http://www.cochrane-handbook.org
   Google Scholar
• Cipriani A Furukawa TA Salanti G Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 2009 373 9665 746 758 19185342
   PubMed Web of Science ®Google Scholar
• Papakostas GI Tolerability of modern antidepressants J Clin Psychiatry 2008 69 Suppl E1 8 13 18494538
   PubMed Web of Science ®Google Scholar
• Wiebe N Vandermeer B Platt RW Klassen TP Moher D Barrowman NJ A systematic review identifes a lack of standardization in methods for handling missing variance data J Clin Epidemiol 2006 59 4 342 353 16549255
   PubMed Web of Science ®Google Scholar
• Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration 2011 Available from: http://www.cochrane-handbook.org
   Google Scholar
• GlaxoSmithKline A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, fexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150 mg–300 mg once daily), extended-release venlafaxine hydrochloride (75 mg–150 mg once daily) and placebo in subjects with major depressive disorder Available from http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=AK130939&studyId=7A3E0BD4-A282-4F67-AB1F-FFC9B215D730&compound=bupropion&type=Compound&letterrange=A-F Date accessed February 2, 2013
   Google Scholar
• GlaxoSmithKline A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, fexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150 mg–300 mg once daily), extended-release venlafaxine hydrochloride (75 mg–150 mg once daily) and placebo in subjects with major depressive disorder Available from http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=101497&studyId=F54FA1DC-4F87-46AF-A8DA-BFEBFCF170B7&compound=bupropion&type=Compound&letterrange=A-F Date accessed February 2, 2013
   Google Scholar
• GlaxoSmithKline A twelve-week, multi-center, randomized, doubleblind, double-dummy, parallel-group, active-controlled, escalating dose study to compare the effects on sexual functioning of bupropion hydrochloride extended-release (WELLBUTRIN® XL, 150–450 mg/day) and extended-release venlafaxine (effexor XR, 75–225 mg/day) in subjects with major depressive disorder Available from http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=100368&studyId=A5B5F2C5-6C67-40EC-9476-DFAA38338F84&compound=bupropion&type=Compound&letterrange=A-F. NCT00316160Date accessed February 2, 2013
   Google Scholar
• Thase ME Clayton AH Haight BR Thompson AH Modell JG Johnston JA A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability J Clin Psychopharmacol 2006 26 5 482 488 16974189
   PubMed Web of Science ®Google Scholar
• Rush AJ Trivedi MH Wisniewski SR STAR*D Study Team Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med 2006 354 12 1231 1242 16554525
   PubMed Web of Science ®Google Scholar
• Hewett K Chrzanowski W Jokinen R Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder J Psychopharmacol (Oxford) 2010 24 4 521 529 19164492
   PubMed Web of Science ®Google Scholar
• Hewett K Chrzanowski W Schmitz M Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR J Psychopharmacol (Oxford) 2009 23 5 531 538 18635695
   PubMed Web of Science ®Google Scholar
• Hewett K Gee MD Krishen A Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR J Psychopharmacol (Oxford) 2010 24 8 1209 1216 19939870
   PubMed Web of Science ®Google Scholar
• Stahl SM Entsuah R Rudolph RL Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression Biological psychiatry 12 15 2002 52 12 1166 1174 12488062
   PubMed Web of Science ®Google Scholar
• Papakostas GI Thase ME Fava M Nelson JC Shelton RC Are antide-pressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents Biological psychiatry 12 1 2007 62 11 1217 1227 17588546
   PubMed Web of Science ®Google Scholar
• Gartlehner G Hansen RA Carey TS Lohr KN Gaynes BN Randolph LC Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis Int Clin Psychopharmacol 2005 20 2 59 69 15729080
   PubMed Web of Science ®Google Scholar
• Thase ME Haight BR Richard N Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials J Clin Psychiatry 2005 66 8 974 981 16086611
   PubMed Web of Science ®Google Scholar